The After Final Consideration Pilot Program 2.0 (AFCP 2.0) has been a valuable tool for U.S. patent applicants since its inception in 2013. By offering […]
The Federal Circuit’s recent denial of Cellect’s en banc petition leaves for another day clarity with respect to the interplay between obviousness-type double patenting and […]
In Re: Cellect, LLC Decided August 28, 2023 Nearly a decade ago, the Federal Circuit held that “the doctrine of obviousness-type double patenting continues to […]
Written description: a death knell to genus claims in biotechnology Brian M Gummow, Alison Care, Karen Mangasarian and James F Haley Jr Haley Guiliano LLP 18 August 2022 Shutterstock\Pixels […]
It has been nearly six months since the EPO updated the Guidelines for Examination at the European Patent Office (“the Guidelines”). We take a look […]
Supplementary protection certificates (SPCs) allow for up to five and half years of additional patent protection for a medicinal product that has been authorised to […]
With the passing of the Trademark Modernization Act of 2020 (TMA), trademark stakeholders will need to familiarize themselves with changes to the Lanham Act, as […]
The end of the BREXIT transition period has no effect on European patents or patent applications. The European Patent Office (EPO) is European in name […]